179 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32616-2/fulltext
178 Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32409-6/fulltext
177 AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy.
http://www.pnas.org/content/114/9/E1688
176 Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607529
175 Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1612674
174 A transistor-like pH nanoprobe for tumour detection and image-guided surgery.
http://www.nature.com/articles/s41551-016-0006
173 Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31594-X/fulltext
172 Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
http://www.nejm.org/doi/full/10.1056/NEJMoa1610497
171 Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607427
170 Dermatologist-level classification of skin cancer with deep neural networks.
http://www.nature.com/nature/journal/v542/n7639/full/nature21056.html
169 Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors.
http://www.pnas.org/content/114/4/740.abstract
168 A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
http://stm.sciencemag.org/content/9/372/eaag2611
167 Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.
http://www.nature.com/nm/journal/v23/n1/abs/nm.4232.html
166 Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation.
http://www.nature.com/nm/journal/v23/n1/abs/nm.4252.html
165 Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32517-X/fulltext
164 Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32455-2/fulltext
163 Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32453-9/fulltext
162 T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1609279
161 Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611406
160 Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611310
159 TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
http://www.nejm.org/doi/full/10.1056/NEJMoa1605949
158 Palbociclib and Letrozole in Advanced Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607303
157 A personalized DC/AML fusion cell vaccine promotes the expansion of leukemia-specific T cells and prolonged remission in patients.
http://stm.sciencemag.org/content/8/368/368ra171.abstract
156 Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
http://www.nejm.org/doi/full/10.1056/NEJMoa1609214
155 Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1609709
154 Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611299
153 Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602252
152 Mutational signatures associated with tobacco smoking in human cancer.
http://science.sciencemag.org/content/354/6312/618
151 Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607751
150 Anti-VEGF therapy enhances mechanical barriers to therapy in colorectal cancer liver metastases by increasing hyaluronan deposition.
http://stm.sciencemag.org/content/8/360/360ra135
149 Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1509277
148 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602253
147 Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1606038
146 Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31388-5/fulltext
145 Cord-Blood Transplantation in Patients with Minimal Residual Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602074?query=featured_home
144 Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
http://www.nejm.org/doi/full/10.1056/NEJMoa1515725
143 Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
http://www.nejm.org/doi/full/10.1056/NEJMoa1604700
142 Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990–2010: a longitudinal analysis.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00577-8/abstract
141 Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30583-9/abstract
140 Genomic Classification and Prognosis in Acute Myeloid Leukemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1516192
|